(Updates with stock price movement in the headline and first paragraph)
ADC Therapeutics (ADCT) gained as much as 4.2% in intraday trading Tuesday after the company said it had completed patient enrollment in its phase 3 confirmatory trial of Zynlonta in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
"We anticipate sharing topline results of the primary endpoint analysis by the end of 2025 once the pre-specified number of events is reached and potentially submitting our supplemental BLA to the US Food and Drug Administration in the first quarter of 2026," said Chief Medical Officer Mohamed Zaki in a statement late Monday.
The stock was up 0.8% in recent trading.
Price: 1.91, Change: +0.01, Percent Change: +0.53
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。